Laffly Emmanuelle, Sodoyer Régis
LCCP, IBS, Institut de Biologie Structurale Jean-Pierre Ebel, 41, rue Jules Horowitz, F-38027 Grenoble, CEA, France.
J Soc Biol. 2006;200(4):325-43. doi: 10.1051/jbio:2006037.
The hybridoma fusion technology, proposed in 1975, gave for the first time an access to murine monoclonal antibodies. The high potential of these new molecules, as laboratory tools, was exploited during the two following decades. Nowadays, antibodies, still omnipresent in both diagnostic and research domains, have progressively invaded the therapeutic field. New technologies, such as phage display and transgenic mice, have been implemented, allowing for the isolation of fully human antibodies. The natural complexity of the antibody molecules and the development of engineering methodologies helped making them ideal candidates for new applications and immunotherapeutic challenges. The present review is a temporary update of the different antibody-derived molecules as well as a walk-through among the techniques recently applied to antibody engineering. In addition it also address an important issue, such as the development of expression systems suitable large-scale production of recombinant antibodies.
1975年提出的杂交瘤融合技术首次实现了鼠源单克隆抗体的制备。在随后的二十年里，这些新分子作为实验室工具的巨大潜力得到了充分利用。如今，抗体在诊断和研究领域仍然无处不在，并逐渐进入了治疗领域。诸如噬菌体展示和转基因小鼠等新技术已经得到应用，使得全人源抗体的分离成为可能。抗体分子的天然复杂性以及工程方法的发展使它们成为新应用和免疫治疗挑战的理想候选者。本综述是对不同抗体衍生分子的临时更新，也是对最近应用于抗体工程的技术的一次梳理。此外，它还探讨了一个重要问题，即适合大规模生产重组抗体的表达系统的开发。
